MAPK1 and metabolic dysfunction-associated steatotic liver disease: This results in hepatic insulin resistance and diabetes, with further metabolic related pathological correlates to hepatic steatosis and non-alcoholic fatty liver disease (NAFLD).[133] However, in another study, when 3T3-L1 adipocytes are isolated from type II diabetic patients, it was observed that there is an increased level of MAPKs signalling as well as p38 activation.